IL291436A - History of 4-disubstituted indole and indazole sulfonamidos as parg inhibitors - Google Patents
History of 4-disubstituted indole and indazole sulfonamidos as parg inhibitorsInfo
- Publication number
- IL291436A IL291436A IL291436A IL29143622A IL291436A IL 291436 A IL291436 A IL 291436A IL 291436 A IL291436 A IL 291436A IL 29143622 A IL29143622 A IL 29143622A IL 291436 A IL291436 A IL 291436A
- Authority
- IL
- Israel
- Prior art keywords
- indazole
- substituted indole
- parg inhibitors
- sulfonamido derivatives
- sulfonamido
- Prior art date
Links
- -1 4-substituted indole Chemical class 0.000 title 1
- 101150003479 Parg gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| PCT/US2020/051486 WO2021055744A1 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291436A true IL291436A (en) | 2022-05-01 |
Family
ID=72744866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291436A IL291436A (en) | 2019-09-20 | 2022-03-16 | History of 4-disubstituted indole and indazole sulfonamidos as parg inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (enExample) |
| EP (1) | EP4031249A1 (enExample) |
| JP (2) | JP2022548690A (enExample) |
| KR (1) | KR20220066922A (enExample) |
| CN (1) | CN114555593A (enExample) |
| AU (1) | AU2020348489A1 (enExample) |
| BR (1) | BR112022004624A2 (enExample) |
| CA (1) | CA3147493A1 (enExample) |
| IL (1) | IL291436A (enExample) |
| MX (1) | MX2022003276A (enExample) |
| TW (1) | TWI873187B (enExample) |
| WO (1) | WO2021055744A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP4413000A1 (en) | 2021-10-04 | 2024-08-14 | FoRx Therapeutics AG | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| IL314887A (en) | 2022-02-14 | 2024-10-01 | Arase Therapeutics Inc | Inhibitors of parg |
| CN116693519A (zh) * | 2022-03-04 | 2023-09-05 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| TW202345809A (zh) * | 2022-03-23 | 2023-12-01 | 美商愛德亞生物科學公司 | 作為parg抑制劑之經哌取代的吲唑化合物 |
| KR20250002563A (ko) * | 2022-04-28 | 2025-01-07 | 다나틀라스 파마슈티컬즈 씨오., 엘티디. | 삼환식 헤테로고리 유도체, 조성물 및 이의 용도 |
| TW202409036A (zh) * | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| AU2023271807A1 (en) | 2022-05-17 | 2025-01-02 | 858 Therapeutics, Inc. | Inhibitors of parg |
| KR20250028378A (ko) * | 2022-06-29 | 2025-02-28 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 5원 및 6원 융합 질소 함유 화합물, 이의 중간체, 제조 방법 및 용도 |
| AU2023310489A1 (en) * | 2022-07-19 | 2025-02-13 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| AR130748A1 (es) * | 2022-10-13 | 2025-01-15 | Hanmi Pharmaceutical Co Ltd | Compuesto heterobicíclico para inhibir la interacción yap-tead y composición farmacéutica que lo comprende |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| CN121335701A (zh) | 2023-04-05 | 2026-01-13 | 艾迪亚生物科学公司 | 用于治疗癌症的包含parg抑制剂和拓扑异构酶抑制剂的联合疗法 |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| AU2024262278A1 (en) * | 2023-04-27 | 2025-12-18 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| WO2024254990A1 (zh) * | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025064745A1 (en) * | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Parg inhibitor |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025067464A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN119859145A (zh) * | 2023-10-20 | 2025-04-22 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| TW202523299A (zh) * | 2023-10-26 | 2025-06-16 | 大陸商上海齊魯製藥研究中心有限公司 | Parg抑制劑 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| TW202539682A (zh) * | 2023-11-21 | 2025-10-16 | 美商858療法股份有限公司 | 使用parg抑制劑對癌症之治療 |
| TW202529739A (zh) * | 2023-11-22 | 2025-08-01 | 美商858療法股份有限公司 | Parg之抑制劑 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| CN118459452B (zh) * | 2024-07-10 | 2024-10-25 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288138B6 (sk) | 1999-02-10 | 2013-11-04 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| JP5865844B2 (ja) * | 2011-01-07 | 2016-02-17 | 大鵬薬品工業株式会社 | 新規インドール、インダゾール誘導体又はその塩 |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) * | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP3697777A1 (en) * | 2017-10-19 | 2020-08-26 | eFFECTOR Therapeutics, Inc. | Benzimidazole-indole inhibitors of mnk1 and mnk2 |
| JP7500555B2 (ja) * | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| TW202345809A (zh) * | 2022-03-23 | 2023-12-01 | 美商愛德亞生物科學公司 | 作為parg抑制劑之經哌取代的吲唑化合物 |
-
2020
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 AU AU2020348489A patent/AU2020348489A1/en active Pending
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 EP EP20786137.8A patent/EP4031249A1/en active Pending
-
2022
- 2022-03-16 IL IL291436A patent/IL291436A/en unknown
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220389003A1 (en) | 2022-12-08 |
| JP2022548690A (ja) | 2022-11-21 |
| KR20220066922A (ko) | 2022-05-24 |
| JP2025016684A (ja) | 2025-02-04 |
| CA3147493A1 (en) | 2021-03-25 |
| TWI873187B (zh) | 2025-02-21 |
| TW202120501A (zh) | 2021-06-01 |
| BR112022004624A2 (pt) | 2022-05-31 |
| WO2021055744A1 (en) | 2021-03-25 |
| EP4031249A1 (en) | 2022-07-27 |
| AU2020348489A1 (en) | 2022-05-05 |
| MX2022003276A (es) | 2022-04-11 |
| JP7781244B2 (ja) | 2025-12-05 |
| CN114555593A (zh) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291436A (en) | History of 4-disubstituted indole and indazole sulfonamidos as parg inhibitors | |
| SG11202010822SA (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| IL282252A (en) | Indole AHR inhibitors and their uses | |
| IL261552B (en) | Spiro-condensed pyrrolidine derivatives that inhibit deubiquitination enzymes (dub) | |
| ZA201904239B (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| IL275948A (en) | History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses | |
| ZA201906395B (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| ZA201907713B (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| IL270726A (en) | Transduced indulin derivatives as inhibitors of dengue virus replication | |
| HUE066348T2 (hu) | Heterociklusos flavon-származékok és az ezekhez kapcsolódó készítmények és eljárások | |
| SI3601225T1 (sl) | Substituirani derivati indolina kot zaviralci replikacije virusa denga | |
| SG11202103142TA (en) | Heterocyclic kinase inhibitors and uses thereof | |
| IL281371A (en) | Indazole carboxamides as kinase inhibitors | |
| IL270616B (en) | Nitrogen-substituted indoles | |
| IL288903A (en) | Indazoles and azaindazoles as lrrk2 repressors | |
| IL290314A (en) | Quinolines as protein kinase inhibitors | |
| IL273974A (en) | Amine-Disubstituted Heterocyclic Compounds as EHMT2 Inhibitors, Their Salts, and Method for Their Synthesis | |
| SMT202200343T1 (it) | Derivati di 1-(4-(isossazol-5-ile)-1h- pirazol-1-ile)-2-metilpropan-2-olo e composti correlati come il-17 e inibitori ifn-gamma per il trattamento di malattie autoimmuni e infiammazioni croniche | |
| SG11202110272SA (en) | Prmt5 inhibitors and uses thereof | |
| ZA202200834B (en) | Isoquinolinone derivatives serving as rock protein kinase inhibitors and use thereof | |
| HK40077359A (en) | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors | |
| IL304356A (en) | Indole derivatives as kinase inhibitors | |
| HK40104879A (en) | Indole derivatives as kinase inhibitors | |
| HK40061556A (en) | Heterocyclic kinase inhibitors and uses thereof | |
| ZA201908398B (en) | N-substituted indole derivatives |